Researchers have focused on potential biological mechanisms underlying cisplatin or cisplatin resistance in ovarian cancers, namely, the regulation of chemical transport, DNA repair mechanisms, survival pathways (e.g., MAPK pathway and PI3K/AKT pathway), and tumor suppressors (Brasseur et al., 2017). This evidence concerns the gene AKT1 and ovarian carcinoma.